3.66
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Low
3.50
High
9.70
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| InflaRx NV | IFRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 3.66 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.66 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 3.50 | 3.73 | 0.23 | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.66 | USD |
InflaRx NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 103.32M | 28.23M | 23.88M | $ - | $ - | -2.36 | -3.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
InflaRx NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IFRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.86 | 3.90 | 3.51 | 3.70 | 246,193 | -0.20 | -5.18% |
| 1 Month | 4.26 | 4.34 | 3.51 | 3.80 | 276,645 | -0.60 | -14.08% |
| 3 Months | 5.80 | 6.38 | 3.51 | 4.65 | 395,329 | -2.14 | -36.9% |
| 6 Months | 4.65 | 6.88 | 3.51 | 4.80 | 333,262 | -0.99 | -21.29% |
| 1 Year | 5.07 | 9.70 | 3.50 | 5.56 | 531,124 | -1.41 | -27.81% |
| 3 Years | 39.00 | 53.10 | 2.17 | 6.53 | 539,772 | -35.34 | -90.62% |
| 5 Years | 15.19 | 53.10 | 2.17 | 6.85 | 480,259 | -11.53 | -75.91% |
InflaRx NV Description
| InflaRx NV is a clinical-stage biopharmaceutical company is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction. |
